Medicure Valuation
Is MPH undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
2/6Valuation Score 2/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of MPH when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: MPH (CA$0.9) is trading above our estimate of fair value (CA$0.16)
Significantly Below Fair Value: MPH is trading above our estimate of fair value.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for MPH?
Key metric: As MPH is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.
| What is MPH's PS Ratio? | |
|---|---|
| PS Ratio | 0.4x |
| Sales | CA$20.93m |
| Market Cap | CA$9.39m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 0.2x |
| Enterprise Value/EBITDA | -4.4x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does MPH's PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 2.3x | ||
CSCI COSCIENS Biopharma | 2x | n/a | CA$13.3m |
SZLS StageZero Life Sciences | 1.2x | n/a | CA$4.9m |
MBX Microbix Biosystems | 1.8x | 22.7% | CA$42.0m |
IBT IBEX Technologies | 4.4x | n/a | CA$35.3m |
MPH Medicure | 0.4x | n/a | CA$9.4m |
Price-To-Sales vs Peers: MPH is good value based on its Price-To-Sales Ratio (0.4x) compared to the peer average (2.3x).
Price to Sales Ratio vs Industry
How does MPH's PS Ratio compare vs other companies in the CA Biotechs Industry?
Price-To-Sales vs Industry: MPH is good value based on its Price-To-Sales Ratio (0.4x) compared to the North American Biotechs industry average (9.3x).
Price to Sales Ratio vs Fair Ratio
What is MPH's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 0.4x |
| Fair PS Ratio | n/a |
Price-To-Sales vs Fair Ratio: Insufficient data to calculate MPH's Price-To-Sales Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
Medexus Pharmaceuticals
CA$58.7m
Operates as a pharmaceutical company in Canada and the United States.
MDP
CA$2.38
7D
12.8%
1Y
60.8%
Verano Holdings
CA$722.2m
Operates as a vertically integrated multi-state cannabis operator in the United States.
VRNO
CA$1.98
7D
-17.2%
1Y
-65.9%
Cresco Labs
CA$525.4m
Cresco Labs Inc., together with its subsidiaries, cultivates, manufactures, and sells retail and medical cannabis products in the United States.
CL
CA$1.67
7D
-8.2%
1Y
-27.7%